Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2

Journal of Medicinal Chemistry

Volumn 59, Issue 18, 2016, Pages 8381-8397

  Váradi, András ^a   Marrone, Gina F ^a   Palmer, Travis C ^a   Narayan, Ankita ^a   Szabó, Márton R ^c   Le Rouzic, Valerie ^a   Grinnell, Steven G ^a   Subrath, Joan J ^a   Warner, Evelyn ^a   Kalra, Sanjay ^a   Hunkele, Amanda ^a   Pagirsky, Jeremy ^a   Eans, Shainnel O ^b   Medina, Jessica M ^b   Xu, Jin ^a   Pan, Ying Xian ^a   Borics, Attila ^c   Pasternak, Gavril W ^a   McLaughlin, Jay P ^b   Majumdar, Susruta ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYMITRAGYNINE; 9 CYANO CORYNANTHEIDINE PSEUDOINDOXYL; 9 FURYL CORYNANTHEIDINE PSEUDOINDOXYL; 9 HYDROXY CORYNANTHEIDINE PSEUDOINDOXYL; 9 O ACETYL CORYNANTHEIDINE PSEUDOINDOXYL; 9 O TRIFLUORO METHANE SULFONYL CORYNANTHEIDINE PSEUDOINDOXYL; 9 PHENYL CORYNANTHEIDINE PSEUDOINDOXYL; ANTINOCICEPTIVE AGENT; BETA ARRESTIN 2; CORYNANTHEIDINE PSEUDOINDOXYL; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR ANTAGONIST; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MITRAGYNINE; MITRAGYNINE PSEUDOINDOXYL; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; N BENZYL MITRAGYNINE PSEUDOINDOXYL; N METHYL MITRAGYNINE PSEUDOINDOXYL; SULFUR 35; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT; RAUWOLFIA ALKALOID;

ADULT; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERSION; BINDING AFFINITY; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEPENDENCE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TOLERANCE; EC50; FEMALE; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PROTEIN TRANSPORT; RECEPTOR BLOCKING; RESPIRATION DEPRESSION; REWARD; STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; HUMAN; METABOLISM; MITRAGYNA; MOLECULAR DOCKING;

ANALGESICS, OPIOID; ANIMALS; BETA-ARRESTIN 2; CELL LINE; HUMANS; MALE; MICE; MITRAGYNA; MOLECULAR DOCKING SIMULATION; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; SECOLOGANIN TRYPTAMINE ALKALOIDS;

EID: 84988713779     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00748     Document Type: Article

References (88)

1. Minami, M.; Satoh, M. Molecular biology of the opioid receptors: structures, functions and distributions Neurosci. Res. 1995, 23, 121-145 10.1016/0168-0102(95)00933-K
2. Eguchi, M. Recent advances in selective opioid receptor agonists and antagonists Med. Res. Rev. 2004, 24, 182-212 10.1002/med.10059
3. Trescot, A. M.; Datta, S.; Lee, M.; Hans, H. Opioid pharmacology Pain Physician 2008, 11, S133-S153
4. Pasternak, G. W. Pharmacological mechanisms of opioid analgesics Clin. Neuropharmacol. 1993, 16, 1-18 10.1097/00002826-199302000-00001
5. Ananthan, S. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics AAPS J. 2006, 8, E118-125 10.1208/aapsj080114
6. Mosberg, H. I.; Yeomans, L.; Anand, J. P.; Porter, V.; Sobczyk-Kojiro, K.; Traynor, J. R.; Jutkiewicz, E. M. Development of a bioavailable mu opioid receptor (MOPr) agonist, delta opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance J. Med. Chem. 2014, 57, 3148-3153 10.1021/jm5002088
7. Váradi, A.; Hosztafi, S.; Le Rouzic, V.; Tóth, G.; Urai, A.; Noszal, B.; Pasternak, G. W.; Grinnell, S. G.; Majumdar, S. Novel 6beta-acylaminomorphinans with analgesic activity Eur. J. Med. Chem. 2013, 69, 786-789 10.1016/j.ejmech.2013.09.031
8. Váradi, A.; Marrone, G. F.; Eans, S. O.; Ganno, M. L.; Subrath, J. J.; Le Rouzic, V.; Hunkele, A.; Pasternak, G. W.; McLaughlin, J. P.; Majumdar, S. Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior ACS Chem. Neurosci. 2015, 6, 1813-1824 10.1021/acschemneuro.5b00153
9. Váradi, A.; Palmer, T. C.; Haselton, N.; Afonin, D.; Subrath, J. J.; Le Rouzic, V.; Hunkele, A.; Pasternak, G. W.; Marrone, G. F.; Borics, A.; Majumdar, S. Synthesis of carfentanil amide opioids using the ugi multicomponent reaction ACS Chem. Neurosci. 2015, 6, 1570-1577 10.1021/acschemneuro.5b00137
10. Law, P. Y.; Reggio, P. H.; Loh, H. H. Opioid receptors: toward separation of analgesic from undesirable effects Trends Biochem. Sci. 2013, 38, 275-282 10.1016/j.tibs.2013.03.003
11. Pradhan, A. A.; Smith, M. L.; Kieffer, B. L.; Evans, C. J. Ligand-directed signalling within the opioid receptor family Br. J. Pharmacol. 2012, 167, 960-969 10.1111/j.1476-5381.2012.02075.x
12. Raehal, K. M.; Bohn, L. M. The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics Neuropharmacology 2011, 60, 58-65 10.1016/j.neuropharm.2010.08.003
13. Bohn, L. M.; Lefkowitz, R. J.; Caron, M. G. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice J. Neurosci. 2002, 22, 10494-10500
14. Dewire, S. M.; Yamashita, D. S.; Rominger, D. H.; Liu, G.; Cowan, C. L.; Graczyk, T. M.; Chen, X. T.; Pitis, P. M.; Gotchev, D.; Yuan, C.; Koblish, M.; Lark, M. W.; Violin, J. D. A G protein-biased ligand at the mu opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine J. Pharmacol. Exp. Ther. 2013, 344, 708-717 10.1124/jpet.112.201616
15. Soergel, D. G.; Subach, R. A.; Burnham, N.; Lark, M. W.; James, I. E.; Sadler, B. M.; Skobieranda, F.; Violin, J. D.; Webster, L. R. Biased agonism of the mu opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers Pain 2014, 155, 1829-1835 10.1016/j.pain.2014.06.011
16. Rives, M. L.; Rossillo, M.; Liu-Chen, L. Y.; Javitch, J. A. 6′-Guanidinonaltrindole (6′-GNTI) is a G protein-biased kappa opioid receptor agonist that inhibits arrestin recruitment J. Biol. Chem. 2012, 287, 27050-27054 10.1074/jbc.C112.387332
17. White, K. L.; Robinson, J. E.; Zhu, H.; DiBerto, J. F.; Polepally, P. R.; Zjawiony, J. K.; Nichols, D. E.; Malanga, C. J.; Roth, B. L. The G protein-biased κ opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo J. Pharmacol. Exp. Ther. 2015, 352, 98-109 10.1124/jpet.114.216820
18. Lovell, K. M.; Frankowski, K. J.; Stahl, E. L.; Slauson, S. R.; Yoo, E.; Prisinzano, T. E.; Aubé, J.; Bohn, L. M. structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias ACS Chem. Neurosci. 2015, 6, 1411-1419 10.1021/acschemneuro.5b00092
19. Zhou, L.; Lovell, K. M.; Frankowski, K. J.; Slauson, S. R.; Phillips, A. M.; Streicher, J. M.; Stahl, E.; Schmid, C. L.; Hodder, P.; Madoux, F.; Cameron, M. D.; Prisinzano, T. E.; Aubé, J.; Bohn, L. M. Development of functionally selective, small molecule agonists at kappa opioid receptors J. Biol. Chem. 2013, 288, 36703-36716 10.1074/jbc.M113.504381
20. Li, J. W.; Vederas, J. C. Drug discovery and natural products: end of an era or an endless frontier? Science 2009, 325, 161-165 10.1126/science.1168243
21. Prisinzano, T. E. Psychopharmacology of the hallucinogenic sage Salvia divinorum Life Sci. 2005, 78, 527-531 10.1016/j.lfs.2005.09.008
22. Prisinzano, T. E. Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuse J. Nat. Prod. 2009, 72, 581-587 10.1021/np8005748
23. Tidgewell, K.; Harding, W. W.; Lozama, A.; Cobb, H.; Shah, K.; Kannan, P.; Dersch, C. M.; Parrish, D.; Deschamps, J. R.; Rothman, R. B.; Prisinzano, T. E. Synthesis of salvinorin A analogues as opioid receptor probes J. Nat. Prod. 2006, 69, 914-918 10.1021/np060094b
24. Tidgewell, K.; Groer, C. E.; Harding, W. W.; Lozama, A.; Schmidt, M.; Marquam, A.; Hiemstra, J.; Partilla, J. S.; Dersch, C. M.; Rothman, R. B.; Bohn, L. M.; Prisinzano, T. E. Herkinorin analogues with differential beta-arrestin-2 interactions J. Med. Chem. 2008, 51, 2421-2431 10.1021/jm701162g
25. Aldrich, J. V.; Kulkarni, S. S.; Senadheera, S. N.; Ross, N. C.; Reilley, K. J.; Eans, S. O.; Ganno, M. L.; Murray, T. F.; McLaughlin, J. P. Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208 ChemMedChem 2011, 6, 1739-1745 10.1002/cmdc.201100113
26. Jansen, K. L.; Prast, C. J. Ethnopharmacology of kratom and the Mitragyna alkaloids J. Ethnopharmacol. 1988, 23, 115-119 10.1016/0378-8741(88)90121-3
27. Karinen, R.; Fosen, J. T.; Rogde, S.; Vindenes, V. An accidental poisoning with mitragynine Forensic Sci. Int. 2014, 245, e29-e32 10.1016/j.forsciint.2014.10.025
28. Kronstrand, R.; Roman, M.; Thelander, G.; Eriksson, A. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend krypton J. Anal. Toxicol. 2011, 35, 242-247 10.1093/anatox/35.4.242
29. McIntyre, I. M.; Trochta, A.; Stolberg, S.; Campman, S. C. Mitragynine 'kratom' related fatality: a case report with postmortem concentrations J. Anal. Toxicol. 2015, 39, 152-155 10.1093/jat/bku137
30. Neerman, M. F.; Frost, R. E.; Deking, J. A drug fatality involving Kratom J. Forensic Sci. 2013, 58, S278-S279 10.1111/1556-4029.12009
31. Macko, E.; Weisbach, J. A.; Douglas, B. Some observations on the pharmacology of mitragynine Arch. Int. Pharmacodyn. Ther. 1972, 198, 145-161
32. Matsumoto, K.; Hatori, Y.; Murayama, T.; Tashima, K.; Wongseripipatana, S.; Misawa, K.; Kitajima, M.; Takayama, H.; Horie, S. Involvement of mu opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa Eur. J. Pharmacol. 2006, 549, 63-70 10.1016/j.ejphar.2006.08.013
33. Matsumoto, K.; Horie, S.; Ishikawa, H.; Takayama, H.; Aimi, N.; Ponglux, D.; Watanabe, K. Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa Life Sci. 2004, 74, 2143-2155 10.1016/j.lfs.2003.09.054
34. Matsumoto, K.; Horie, S.; Takayama, H.; Ishikawa, H.; Aimi, N.; Ponglux, D.; Murayama, T.; Watanabe, K. Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa Life Sci. 2005, 78, 2-7 10.1016/j.lfs.2004.10.086
35. Matsumoto, K.; Mizowaki, M.; Suchitra, T.; Murakami, Y.; Takayama, H.; Sakai, S.-i.; Aimi, N.; Watanabe, H. Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems Eur. J. Pharmacol. 1996, 317, 75-81 10.1016/S0014-2999(96)00714-5
36. Matsumoto, K.; Mizowaki, M.; Suchitra, T.; Takayama, H.; Sakai, S.; Aimi, N.; Watanabe, H. Antinociceptive action of mitragynine in mice: evidence for the involvement of supraspinal opioid receptors Life Sci. 1996, 59, 1149-1155 10.1016/0024-3205(96)00432-8
37. Matsumoto, K.; Yamamoto, L. T.; Watanabe, K.; Yano, S.; Shan, J.; Pang, P. K.; Ponglux, D.; Takayama, H.; Horie, S. Inhibitory effect of mitragynine, an analgesic alkaloid from Thai herbal medicine, on neurogenic contraction of the vas deferens Life Sci. 2005, 78, 187-194 10.1016/j.lfs.2005.04.042
38. Takayama, H.; Ishikawa, H.; Kitajima, M.; Aimi, N. Formation of an unusual dimeric compound by lead tetraacetate oxidation of a corynanthe-type indole alkaloid, mitragynine Chem. Pharm. Bull. 2002, 50, 960-963 10.1248/cpb.50.960
39. Takayama, H.; Ishikawa, H.; Kurihara, M.; Kitajima, M.; Aimi, N.; Ponglux, D.; Koyama, F.; Matsumoto, K.; Moriyama, T.; Yamamoto, L. T.; Watanabe, K.; Murayama, T.; Horie, S. Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands J. Med. Chem. 2002, 45, 1949-1956 10.1021/jm010576e
40. Zarembo, J. E.; Douglas, B.; Valenta, J.; Weisbach, J. A. Metabolites of mitragynine J. Pharm. Sci. 1974, 63, 1407-1415 10.1002/jps.2600630916
41. Yamamoto, L. T.; Horie, S.; Takayama, H.; Aimi, N.; Sakai, S.; Yano, S.; Shan, J.; Pang, P. K.; Ponglux, D.; Watanabe, K. Opioid receptor agonistic characteristics of mitragynine pseudoindoxyl in comparison with mitragynine derived from Thai medicinal plant Mitragyna speciosa Gen. Pharmacol. 1999, 33, 73-81 10.1016/S0306-3623(98)00265-1
42. Ponglux, D.; Wongseripipatana, S.; Takayama, H.; Kikuchi, M.; Kurihara, M.; Kitajima, M.; Aimi, N.; Sakai, S. A New Indole Alkaloid, 7 alpha-Hydroxy-7H-mitragynine, from Mitragyna speciosa in Thailand Planta Med. 1994, 60, 580-581 10.1055/s-2006-959578
43. Mercado-Marin, E. V.; Garcia-Reynaga, P.; Romminger, S.; Pimenta, E. F.; Romney, D. K.; Lodewyk, M. W.; Williams, D. E.; Andersen, R. J.; Miller, S. J.; Tantillo, D. J.; Berlinck, R. G. S.; Sarpong, R. Total synthesis and isolation of citrinalin and cyclopiamine congeners Nature 2014, 509, 318-324 10.1038/nature13273
44. Váradi, A.; Marrone, G. F.; Palmer, T. C.; Hunkele, A.; Le Rouzic, V.; Pasternak, G. W.; Pan, Y.-X.; McLaughlin, J. P.; Majumdar, S. Mitragyna alkaloids revisited: pharmacology of mitragynine and related natural products. In Poster Presentation. Proceedings of the International Narcotics Research Conference 2015, Phoenix, AZ, June 15-19, 2015.
45. Besnard, J.; Ruda, G. F.; Setola, V.; Abecassis, K.; Rodriguiz, R. M.; Huang, X. P.; Norval, S.; Sassano, M. F.; Shin, A. I.; Webster, L. A.; Simeons, F. R.; Stojanovski, L.; Prat, A.; Seidah, N. G.; Constam, D. B.; Bickerton, G. R.; Read, K. D.; Wetsel, W. C.; Gilbert, I. H.; Roth, B. L.; Hopkins, A. L. Automated design of ligands to polypharmacological profiles Nature 2012, 492, 215-220 10.1038/nature11691
46. Rossi, G. C.; Pan, Y.-X.; Brown, G. P.; Pasternak, G. W. Antisense mapping the MOR-1 opioid receptor: Evidence for alternative splicing and a novel morphine-6b-glucuronide receptor FEBS Lett. 1995, 369, 192-196 10.1016/0014-5793(95)00757-Z
47. Rossi, G. C.; Pan, Y.-X.; Cheng, J.; Pasternak, G. W. Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor Life Sci. 1994, 54, PL375-PL379 10.1016/0024-3205(94)90038-8
48. Standifer, K. M.; Chien, C.-C.; Wahlestedt, C.; Brown, G. P.; Pasternak, G. W. Selective loss of d opioid analgesia and binding by antisense oligodeoxynucleotides to a d opioid receptor Neuron 1994, 12, 805-810 10.1016/0896-6273(94)90333-6
49. Pasternak, K. R.; Rossi, G. C.; Zuckerman, A.; Pasternak, G. W. Antisense mapping KOR-1: evidence for multiple kappa analgesic mechanisms Brain Res. 1999, 826, 289-292 10.1016/S0006-8993(99)01294-9
50. Pan, Y.-X.; Pasternak, G. W. Molecular Biology of Mu Opioid Receptors. In The Opiate Receptors, 2 nd ed.; Pasternak, G. W., Ed.; Springer: New York, 2011; pp 121-160.
51. Pasternak, G. W.; Pan, Y.-X. Mu opioids and their receptors: Evolution of a concept Pharmacol. Rev. 2013, 65, 1257-1317 10.1124/pr.112.007138
52. Pan, Y.-X.; Xu, J.; Mahurter, L.; Bolan, E. A.; Xu, M. M.; Pasternak, G. W. Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 14084-14089 10.1073/pnas.241296098
53. Xu, J.; Xu, M.; Hurd, Y. L.; Pasternak, G. W.; Pan, Y. X. Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene J. Neurochem. 2009, 108, 962-972 10.1111/j.1471-4159.2008.05833.x
54. Pan, Y. X.; Xu, J.; Xu, M.; Rossi, G. C.; Matulonis, J. E.; Pasternak, G. W. Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 4917-4922 10.1073/pnas.0811586106
55. Lu, Z.; Xu, J.; Rossi, G. C.; Majumdar, S.; Pasternak, G. W.; Pan, Y.-X. Mediation of opioid analgesia by a truncated 6-transmembrane GPCR J. Clin. Invest. 2015, 125, 2626-2630 10.1172/JCI81070
56. Tryba, M.; Gehling, M. Clonidine - a potent analgesic adjuvant Curr. Opin. Anaesthesiol. 2002, 15, 511-517 10.1097/00001503-200210000-00007
57. Schiller, P. W.; Fundytus, M. E.; Merovitz, L.; Weltrowska, G.; Nguyen, T. M. D.; Lemieux, C.; Chung, N. N.; Coderre, T. J. The opioid μ agonist/δ antagonist DIPP-NH2[ψ] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats J. Med. Chem. 1999, 42, 3520-3526 10.1021/jm980724+
58. Ananthan, S.; Saini, S. K.; Dersch, C. M.; Xu, H.; McGlinchey, N.; Giuvelis, D.; Bilsky, E. J.; Rothman, R. B. 14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects J. Med. Chem. 2012, 55, 8350-8363 10.1021/jm300686p
59. Healy, J. R.; Bezawada, P.; Shim, J.; Jones, J. W.; Kane, M. A.; MacKerell, A. D.; Coop, A.; Matsumoto, R. R. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities ACS Chem. Neurosci. 2013, 4, 1256-1266 10.1021/cn4000428
60. Schiller, P. W.; Weltrowska, G.; Berezowska, I.; Nguyen, T. M. D.; Wilkes, B. C.; Lemieux, C.; Chung, N. N. The TIPP opioid peptide family: Development of d antagonists, d agonists, and mixed m agonist/d antagonists Biopolymers 1999, 51, 411-425 10.1002/(SICI)1097-0282(1999)51:6<411::AID-BIP4>3.0.CO;2-Z
61. Abdelhamid, E. E.; Sultana, M.; Portoghese, P. S.; Takemori, A. E. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice J. Pharmacol. Exp. Ther. 1991, 258, 299-303
62. Hepburn, M. J.; Little, P. J.; Gingras, J.; Kuhn, C. M. Differential effects of naltrindole on morphine-induced tolerance and physical dependence in rats J. Pharmacol. Exp. Ther. 1997, 281, 1350-1356
63. Kest, B.; Lee, C. E.; McLemore, G. L.; Inturrisi, C. E. An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice Brain Res. Bull. 1996, 39, 185-188 10.1016/0361-9230(95)02092-6
64. Zhu, Y.; King, M. A.; Schuller, A. G.; Nitsche, J. F.; Reidl, M.; Elde, R. P.; Unterwald, E.; Pasternak, G. W.; Pintar, J. E. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice Neuron 1999, 24, 243-252 10.1016/S0896-6273(00)80836-3
65. Charbogne, P.; Kieffer, B. L.; Befort, K. 15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse Neuropharmacology 2014, 76, 204-217 10.1016/j.neuropharm.2013.08.028
66. Bohn, L. M.; Gainetdinov, R. R.; Sotnikova, T. D.; Medvedev, I. O.; Lefkowitz, R. J.; Dykstra, L. A.; Caron, M. G. Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice J. Neurosci. 2003, 23, 10265-10273
67. Rankovic, Z.; Brust, T. F.; Bohn, L. M. Biased agonism: An emerging paradigm in GPCR drug discovery Bioorg. Med. Chem. Lett. 2016, 26, 241-250 10.1016/j.bmcl.2015.12.024
68. Lefkowitz, R. J.; Shenoy, S. K. Transduction of receptor signals by beta-arrestins Science 2005, 308, 512-517 10.1126/science.1109237
69. Correll, C. C.; McKittrick, B. A. Biased ligand modulation of seven transmembrane receptors (7TMRs): Functional implications for drug discovery J. Med. Chem. 2014, 57, 6887-6896 10.1021/jm401677g
70. Bohn, L. M.; Lefkowitz, R. J.; Gainetdinov, R. R.; Peppel, K.; Caron, M. G.; Lin, F. T. Enhanced morphine analgesia in mice lacking beta-arrestin 2 Science 1999, 286, 2495-2498 10.1126/science.286.5449.2495
71. Bohn, L. M.; Gainetdinov, R. R.; Lin, F. T.; Lefkowitz, R. J.; Caron, M. G. Mu opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence Nature 2000, 408, 720-723 10.1038/35047086
72. Raehal, K. M.; Walker, J. K.; Bohn, L. M. Morphine side effects in beta-arrestin 2 knockout mice J. Pharmacol. Exp. Ther. 2005, 314, 1195-1201 10.1124/jpet.105.087254
73. Takayama, H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa Chem. Pharm. Bull. 2004, 52, 916-928 10.1248/cpb.52.916
74. Granier, S.; Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Weis, W. I.; Kobilka, B. K. Structure of the delta opioid receptor bound to naltrindole Nature 2012, 485, 400-404 10.1038/nature11111
75. Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Mathiesen, J. M.; Sunahara, R. K.; Pardo, L.; Weis, W. I.; Kobilka, B. K.; Granier, S. Crystal structure of the mu opioid receptor bound to a morphinan antagonist Nature 2012, 485, 321-326 10.1038/nature10954
76. Huang, N.; Shoichet, B. K.; Irwin, J. J. Benchmarking sets for molecular docking J. Med. Chem. 2006, 49, 6789-6801 10.1021/jm0608356
77. Huang, W.; Manglik, A.; Venkatakrishnan, A. J.; Laeremans, T.; Feinberg, E. N.; Sanborn, A. L.; Kato, H. E.; Livingston, K. E.; Thorsen, T. S.; Kling, R. C.; Granier, S.; Gmeiner, P.; Husbands, S. M.; Traynor, J. R.; Weis, W. I.; Steyaert, J.; Dror, R. O.; Kobilka, B. K. Structural insights into [micro] opioid receptor activation Nature 2015, 524, 315-321 10.1038/nature14886
78. Majumdar, S.; Burgman, M.; Haselton, N.; Grinnell, S.; Ocampo, J.; Pasternak, A. R.; Pasternak, G. W. Generation of novel radiolabeled opiates through site-selective iodination Bioorg. Med. Chem. Lett. 2011, 21, 4001-4004 10.1016/j.bmcl.2011.05.008
79. Majumdar, S.; Grinnell, S.; Le Rouzic, V.; Burgman, M.; Polikar, L.; Ansonoff, M.; Pintar, J.; Pan, Y. X.; Pasternak, G. W. Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 19778-19783 10.1073/pnas.1115231108
80. Pickett, J. E.; Váradi, A.; Palmer, T. C.; Grinnell, S. G.; Schrock, J. M.; Pasternak, G. W.; Karimov, R. R.; Majumdar, S. Mild, Pd-catalyzed stannylation of radioiodination targets Bioorg. Med. Chem. Lett. 2015, 25, 1761-1764 10.1016/j.bmcl.2015.02.055
81. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent J. Biol. Chem. 1951, 193, 265-275
82. Bolan, E. A.; Pan, Y. X.; Pasternak, G. W. Functional analysis of MOR-1 splice variants of the mouse mu opioid receptor gene Oprm Synapse 2004, 51, 11-8 10.1002/syn.10277
83. Haley, T. J.; McCormick, W. G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse Br. J. Pharmacol. Chemother. 1957, 12, 12-15 10.1111/j.1476-5381.1957.tb01354.x
84. Rossi, G. C.; Brown, G. P.; Leventhal, L.; Yang, K.; Pasternak, G. W. Novel receptor mechanisms for heroin and morphine-6b -glucuronide analgesia Neurosci. Lett. 1996, 216, 1-4 10.1016/0304-3940(96)12976-1
85. Rossi, G. C.; Standifer, K. M.; Pasternak, G. W. Differential blockade of morphine and morphine-6b-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein a subunits in rats Neurosci. Lett. 1995, 198, 99-102 10.1016/0304-3940(95)11977-5
86. Rossi, G. C.; Su, W.; Leventhal, L.; Su, H.; Pasternak, G. W. Antisense mapping DOR-1 in mice: further support for delta receptor subtypes Brain Res. 1997, 753, 176-179 10.1016/S0006-8993(97)00081-4
87. Paul, D.; Pasternak, G. W. Differential blockade by naloxonazine of two m opiate actions: analgesia and inhibition of gastrointestinal transit Eur. J. Pharmacol. 1988, 149, 403-404 10.1016/0014-2999(88)90680-2
88. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Liu, W.; Thompson, A. A.; Huang, X. P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human kappa opioid receptor in complex with JDTic Nature 2012, 485, 327-332 10.1038/nature10939